The War Department Just Put $80 Million Behind Homegrown Pharma Ingredients. Finish the Onshoring
On Oct. 17, the Office of Strategic Capital announced an $80 million conditional loan to Antheia to make key drug starting materials and APIs in America. In our view, essential medicines should not depend on foreign factories — and a conditional loan is a start, not a finish line.
By Clara Hughes
ALTAS WORLD NEWS OPINION | By Clara Hughes, Chief Opinion Editor | October 18, 2026 | 7-min read Most Americans never think about where a generic pill's active ingredients are cooked. They should. On Friday, the Department of War's Office of Strategic Capital announced an $80 million conditional loan commitment with Antheia, Inc., to scale domestic production of key starting materials and active pharmaceutical ingredients for generic drugs [1]. In our view, that is exactly the kind of industrial muscle America should rebuild — before the next shortage arrives with a foreign shipping delay attached. Key Takeaways OSC announced an $80 million conditional loan commitment with Antheia on Oct. 17 to expand U.S. production of KSMs and APIs for generics [1]. OSC says the vast majority of KSMs and APIs are manufactured outside the United States today [1]. The deal advances President Trump's Executive Order 13944 on making essential medicines and critical inputs in America [1][2]. Antheia uses bioengineered yeast to convert sugar into KSMs and APIs in a one-step fermentation process; it currently relies on contract manufacturers abroad [1]. The commitment is conditional: Antheia must still clear financial, legal, technical and diligence